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Chronic transplant dysfunction, a major impediment to
long-term allograft survival, is caused by several factors
including an ongoing alloimmune response termed chronic
rejection. To define some of these factors further, we selected
107 patients mismatched to their donors from 623 patients
transplanted at a single center. Patients were categorized
according to their immunosuppressive treatment and further
divided into those with stable or chronic allograft dysfunction.
Donor human lymphocyte antigen allopeptide-specific T-cell
lines were then generated from stable patients and those
with biopsy-proven chronic allograft nephropathy. Increased
amounts of CD4þCD25þ regulatory T cells (Tregs) and Treg-
associated gene expression profiles were found in cell lines
derived from the patients with stable compared with those
with chronic allograft dysfunction. Furthermore, a higher
percentage of Tregs was found in patients with stable graft
function on tacrolimus-based compared with cyclosporine-
based immunosuppression protocols. Patients with stable
graft function had a significantly higher expression of
interleukin (IL)-4 and IL-10, whereas the cytokines IL-2, IL-17,
and interferon-c were significantly higher in patients with
allograft dysfunction in vitro. Thus, enhancing the operational
role of naturally occurring donor-specific Tregs in allograft
recipients by adjusting the immunosuppression protocol may
be advantageous particularly for patients with ongoing
chronic rejection.
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During the past two decades, the introduction of the
calcineurin inhibitors cyclosporine A (CsA) and tacrolimus
has significantly improved 1-year kidney allograft survival.
However, long-term graft function often remains suboptimal
because of the development of chronic allograft dysfunction
(CAD). Chronic rejection has an important role in the
development and progression of chronic graft damage. The
alloimmune response is influenced by a specialized subset of
regulatory T cells (Tregs) that participate in the maintenance
of immune homeostasis.1,2 Tregs can modify rejection
episodes as they are able to downregulate activated
allospecific T cells.1–3 It has also been shown that Tregs can
actively maintain hyporesponsiveness to alloantigens in renal
transplant patients4,5 and that calcineurin-dependant signal-
ing has an important role in the expansion of Tregs.6 So far,
only few data have been reported with respect to the effect of
the different calcineurin inhibitors tacrolimus and CsA on
the prevalence of donor antigen-specific Tregs after kidney
transplantation. Furthermore, the association between graft
function and the prevalence of Tregs in the graft recipient is
not clear. A quantitative effect of calcineurin inhibitors on
Tregs could not be detected in kidney and lung transplanted
patients;7,8 however, an effect of these drugs could be
detected in CD8þ CD28 T cells.8
There is some evidence that tacrolimus-based immuno-
suppressive protocols might preserve graft function better
than CsA-based protocols,9 possibly because tacrolimus
might better control subacute immune responses in the
allograft, thus reducing chronic rejection more effectively
than CsA. The relative effect of the different calcineurin
inhibitors on Tregs may explain the different efficacies
of tacrolimus compared with CsA. This is supported by
observations demonstrating that tacrolimus had a protective
effect on Tregs in atopic dermatitis.10 So far, only limited
data are available characterizing Tregs after organ transplan-
tation, particularly with respect to the immunosuppressive
protocol.
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RESULTS
Patients
From a total of 107 patients selected for this study, a greater
number of patients on tacrolimus (Tac; Tac/mycophenolate
mofetil (MMF)/steroids) had stable graft function (n¼ 20/
30, 66.7%) as compared with patients receiving CsA either
with or without MMF (CsA/MMF/steroids, n¼ 21/47
(44.7%); CsA/steroids, n¼ 11/30 (36.7%)). Of the 55 patients
classified as having CAD, a total of 24 (43.6%) patients were
biopsied and had evidence of transplant glomerulopathy,
vasculopathy, interstitial fibrosis, and when detectable,
tubular atrophy. A total of 19 cell lines were generated
from these patients with biopsy-proven chronic rejection
(Figure 1). Eighteen cell lines were generated from matched
stable transplant patients. Three out of five patients in the
CsA/steroid group, no patients in the CsA/MMF/steroid
group, and 2/16 patients in the Tac/MMF/steroid group
received anti-T-lymphocyte globulin-induction therapy, but
there were no differences with respect to age, gender, human
lymphocyte antigen (HLA) mismatch, serum creatinine,
number of acute rejections, and cold ischemia time and the
development of chronic allograft dysfunction. Twelve hour
trough tacrolimus and CsA serum levels are presented as
mean values (ng/ml) and range in both representative groups
(Tac/MMF/steroid and CsA/MMF/steroid). For stable pa-
tients, the mean Tac level at 24 months was 11±2.7 ng/ml
(range 6.2–16.1) and for CAD patients at 10.3±2.6 ng/ml
(range 4.7–15.2). The mean CsA level at 24 months for stable
patients was 142.7±34.5 ng/ml (range 97.1–203.2) and for
CAD patients 135.2±37.7 ng/ml (range 84.5–234.1; Table 1).
Comparison of graft function in the different groups of
patients
Serum creatinine levels were similar throughout the observa-
tion period in stable patients on tacrolimus- and CsA-based
immunosuppression. Patients with CAD receiving CsA-based
immunosuppressive therapy had increasing creatinine levels,
630 Patients
523 107
CsA/ster
Stable
Patients
Cell lines
CsA, Cyclosporin A; MMF, mycophenolate mofetil; stable, stable renal function; ster, steroids; Tac, tacrolimus;
creatinine ≤1.6 mg/dl; CAD, chronic allograft dysfunction; creatinine >1.6 mg/dl; Performed cell lines
9 2 16 3 13 8 18 8 12 8 82
11 19 21 26 20 10
CAD Stable CAD Stable CAD
CsA/MMF/ster Tac/MMF/ster
DR mismatched
Figure 1 | Study patients flow chart. Of 630 transplanted
patients, 107 were human lymphocyte antigen DR mismatched
with their donors for the available donor-specific peptides and
selected for further analysis. The patients were categorized
according to their creatinine levels. Patients with a creatinine
p1.6mg/dl were considered to have stable graft function (stable)
and those with a creatinine 41.6mg/dl and biopsy-proven
chronic allograft nephropathy as chronic allograft dysfunction
(CAD). T-cell lines were generated from patients with stable
function or biopsy-proven CAD.
Table 1 | Demographic data of the patients from whom T-cell lines were generated (24 months after Tx)
CsA/steroids
(n=5)
CsA/MMF/steroids
(n=16)
Tac/MMF/steroids
(n=16)
Stable CAD Stable CAD Stable CAD
Recipient demographics
Number of recipients (n=107) 2 3 8 8 8 8
Age (mean±s.d. in years) 44.6 46.4 47.5±4.9 52.9±7.6 56.4±9.8 59.9±7.1
Gender (%)
Female 0 0 0 0 0 0
Male 100 100 100 100 100 100
HLA mismatch (number of mismatches of six HLA Ag, in mean±s.d.) 1.5 2.3 2.8±0.9 3.1±1.1 2.8±0.9 3.1±1.5
Serum creatinine (mean±s.d. in mg/dl) 1.2 2.6 1.3±0.2a 2.5±0.2a 0.9±0.1b 2.2±0.3b
CsA/Tac trough level (mean±s.d. in mg/dl) and range ND ND 142.7±34.5 135.2±37.7 11±2.7 10.3±2.6
97.1–203.2 84.5–234.1 6.2–16.1 4.7–15.2
Proteinuria 41 g/24 h (number of patients/group) 0 1 0 3 0 2
Acute rejection (number of patients/group) 0 1 0 2 0 2
Biopsy (Banff classification of chronic allograft nephropathy or description) 0 3 0 8 0 8
Donor characteristics
Type of donor (number/group)
Deceased 2 3 8 8 8 8
Living 0 0 0 0 0 0
Cold ischemia time (mean±s.d. in hours) 10 11.5 15.3±5.1 13.6±5.3 14.6±6.9 15.3±5.8
Abbreviations: CAD, chronic allograft dysfunction; CsA, cyclosporine A; HLA, human lymphocyte antigen; MMF, mycophenolate mofetil; ND, not determined; stable, stable
renal function; Tac, tacrolimus; Tx, transplantation.
aCsA/MMF/ster versus Tac/MMF/ster Po0.005.
bCsA/MMF/ster versus Tac/MMF/ster CAD, Po0.01.
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whereas patients on tacrolimus had quite constant creatinine
levels during the observation period (Figure 2); however,
none of the grafts were lost by 60 months.
Cytokine analysis in the serum of transplanted patients
In both the sera of patients from the CsA/MMF/steroid and
Tac/MMF/steroid groups, cytokine expression profiles were
measured at 24 months, the time point when T-cell lines were
generated, and at 60 months after transplantation. Generally,
patients with CAD expressed more interleukin (IL)-2, IL-2R,
IL-17, and interferon (IFN)-g than patients with stable graft
function (Figure 3). Interestingly, the patients with stable
function expressed more IL-4 and IL-10 in both groups. We
observed that patients on Tac/MMF/steroids with stable graft
function expressed a higher amount of IL-10 than those
on CsA/MMF/steroids at 24 and 60 months (Po0.05).
In addition, the serum concentrations of IL-2 and IFN-g were
higher in patients on CsA/MMF/steroids with CAD than
those on Tac/MMF/steroids at 24 and 60 months time points
(Po0.001).
Flow cytometric analysis of CD4þCD25þ T cells
Higher percentages of CD4þCD25þ T cells were observed
in T-cell lines generated from patients with stable graft
function as compared with those generated from patients
with CAD in both groups (CsA/MMF/steroids and Tac/
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Figure 3 |Cytokine expression in the serum of patients at 24 and 60 months after transplantation. Patients with chronic allograft
dysfunction (CAD) expressed significantly more interleukin (IL)-2, IL-2R, IL-17, and interferon (IFN)-g than patients with stable renal function.
Patients with stable graft function expressed more IL-4 and IL-10, irrespective of the immunosuppressive protocol. The P-values indicate the
significant differences between patients with CAD and stable renal function 24 months after the transplantation (the time point when the
T-cell lines were generated) and 60 months after the transplantation. CsA, cyclosporine A; MMF, mycophenolate mofetil; ster, steroid;
Tac, tacrolimus.
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Figure 2 | Serum creatinine after transplantation. Creatinine levels were similar during the observation period in stable patients (stable)
on tacrolimus- (Tac/MMF/ster) and CsA (CsA/MMF/ster)-based immunosuppression. Patients with chronic allograft dysfunction (CAD)
receiving CsA tended to have increasing creatinine levels over time as compared with patients on tacrolimus. Creatinine was measured on
day 0 and 12, 24 (generation of T-cell lines, CsA/MMF/ster versus Tac/MMF/ster: 2.6±0.05 versus 2.3±0, Po0.01), 48, and 60 months after
transplantation. Each dot represents one patient; the horizontal lines mark the mean value of the measured creatinine concentration.
CsA, cyclosporine A; MMF, mycophenolate mofetil; ster, steroid; Tac, tacrolimus.
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MMF/steroids, Po0.0001). In addition, the proportion
of CD4þCD25þ was significantly increased in T cell
lines generated from patients with stable graft function on
Tac/MMF/steroid protocol as compared with stable patients
on CsA/MMF/steroids (Po0.0001; Table 2).
Real-time PCR analysis of Foxp3 expression in PBMCs from
patients with stable graft function and on tacrolimus protocol
To ascertain whether the high levels of CD25 expression in
CD4þ T cells in tacrolimus-treated patients reflected a
regulatory phenotype, we evaluated mRNA expression of
Foxp3 (refs. 6, 11, 12). Peripheral blood mononuclear cells
(PBMCs) from the patients with stable graft function on Tac/
MMF/steroids had a 2- to 4.5-fold higher gene expression of
CD4, CD25, CTLA-4, Foxp3, and IL-10 as compared with
patients treated with CsA/MMF/steroids and stable graft
function (Figure 4). No significant differences in expression
of cytokines were observed between tacrolimus- and CsA-
treated patients with chronic allograft dysfunction, except for
the expression of IFN-g, which was higher in the CsA-treated
patients. The expression of transforming growth factor
(TGF)-b was significantly higher in CAD patients, the
difference between Tac- and CsA-based regimen was not
statistically different.
Morphological and functional characterization of T-cell lines
All T-cell lines were generated (24 months after transplanta-
tion) by repeated stimulation (3 times) of PBMCs from
patients with stable graft function and patients with CAD
with the appropriate mismatched donor-derived HLA-DR
peptides (Table 2). The proliferative response of the T-cell
lines to the mismatched donor-derived and irrelevant
(control) HLA-DR peptides was tested.
T-cell lines generated from patients with CAD had a
higher proliferative response as compared with those from
patients with stable graft function (Figure 5). No significant
proliferation above base line was observed after stimulation
with irrelevant HLA-DR control peptides in the T-cell lines
generated from either patient group (data not shown).
CD4þ and CD8þ T cells were present in all the T-cell
lines independent of the immunosuppressive protocol.
T-cell lines generated from PBMCs of patients with stable
graft function contained higher amounts of CD4þCD25þ
cells, as compared with patients with CAD (Table 2).
Patients with stable function treated with tacrolimus had a
higher proportion of CD4þCD25þ cells as compared with
patients on CsA with stable function (Table 2), suggesting a
higher proportion of Tregs in patients treated with
Tac/MMF/steroids.
Regulatory function of T cells from patients with
stable graft function
We next investigated whether the T-cell lines generated from
patients with stable graft function were able to regulate the
alloimmune responses of T cells from patients with CAD. We
set up a co-culture system in which T-cell lines generated
from patients with stable graft function were irradiated
(to prevent their proliferation) and incubated with T cells
from patients with CAD together with the relevant HLA-DR
allopeptides in vitro.13,14 T-cell lines generated from
patients with CAD and on tacrolimus protocol showed a
higher proliferative response to their specific HLA-DR
allopeptide, as compared with the T-cell lines generated
from patients with stable graft function. The addition of
irradiated T-cell lines from the stable patients significantly
inhibited the proliferative response of the T-cell lines derived
Table 2 | Characterization of T-cell lines generated from
patients with chronic allograft dysfunction and stable
renal function
Phenotype (%)
Cell lines
HLA
mismatch CD3+CD8+ CD3+CD4+ CD4+CD25+
CsA/MMF/ster
CAD
1 DR3 8.8 42.8 0.8
2 DR2 8.1 37.3 0.6
3 DR2 5.9 48.5 0.9
4 DR3 9.2 39.8 0.7
5 DR4 7.5 38.9 1.0
6 DR1 9.6 43.1 2.5
7 DR1 9.0 49.0 0.8
8 DR4 6.1 41.9 0.9
Mean±s.d. 8.0±1.4 42.7±4.2 1.0±0.6
Stable
1 DR7 6.7 40.5 2.2
2 DR7 3.7 33.1 3.7
3 DR1 5.9 29.7 4.6
4 DR4 7.8 35.9 2.9
5 DR2 5.1 41.5 4.8
6 DR2 4.7 34.8 4.2
7 DR1 10.1 42.0 4.6
8 DR3 3.1 37.9 3.9
Mean±s.d. 5.9±2.3 36.9±4.4 3.9±0.9
Tac/MMF/ster
CAD
1 DR1 5.9 39.9 1.2
2 DR2 10.3 35.5 1.5
3 DR2 6.4 32.1 0.8
4 DR7 5.5 34.9 2.3
5 DR2 6.0 34.5 1.4
6 DR1 3.2 37.6 3.1
7 DR2 12.6 35.8 0.7
8 DR3 9.5 45.7 1.0
Mean±s.d. 7.4±3.1 37.0±4.2 8.0±1.4
Stable
1 DR2 5.0 30.2 8.1
2 DR1 4.1 30.9 5.4
3 DR3 4.8 32.4 7.0
4 DR4 5.7 34.1 8.6
5 DR1 3.8 33.3 6.9
6 DR1 3.7 26.1 8.2
7 DR3 5.1 16.7 8.4
8 DR2 4.9 27.4 7.5
Mean±s.d. 4.6±0.7 28.9±5.6 7.5±1.1
Abbreviations: CAD, chronic allograft dysfunction; CsA, cyclosporine A; HLA, human
lymphocyte antigen; MMF, mycophenolate mofetil; stable, stable renal function;
ster, steroid; Tac, tacrolimus.
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from CAD patients (53.3%; Figure 5). These effects were
less pronounced in T-cell lines from patients on CsA (38.7%;
Figure 5).
To further dissect the mechanisms of regulation, we
measured the proliferation by the T-cell lines in the presence
or absence of neutralizing IL-10 monoclonal antibody (mAb)
or isotype-matched control. Incubation with neutralizing
IL-10 mAb enhanced the proliferative response of the
co-cultured T cells, as compared with the response without
IL-10 mAb. Interestingly, incubation of T cells generated
from stable patients with neutralizing IL-10 mAb increased
the proliferative response, as compared with the response
of those cells without neutralizing IL-10 mAb. Our data
demonstrate a regulatory function of HLA-DR allopeptide-
specific T-cell lines derived from patients with stable graft
function in human transplant patients and suggest that this is
at least in part dependent on IL-10 production.
DISCUSSION
From several clinical studies it is known that patients on
tacrolimus-based immunosuppression had lower serum
creatinine values and higher glomerular filtration rates, as
compared with patients on CsA-based immunosuppres-
sion.9,15 The reason for this effect is not entirely clear yet.
In our study, we also observed better renal function in a
greater proportion of patients on an immunosuppressive
protocol consisting of Tac/MMF/steroids, as compared
with patients on CsA/MMF/steroids. However, it has been
demonstrated that chronic rejection is an important
contributor to worsening renal allograft function.16 It is
believed that tacrolimus more effectively controls the
alloimmune response as compared with CsA, thus inhibiting
subacute as well as chronic rejection, leading to improved
graft function and potentially longer graft survival. This is
supported by the observation of lower rates of acute rejection
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Figure 4 |Gene analysis of peripheral blood mononuclear cells (PBMCs) from patients at 24 months after transplantation.
PBMCs from patients with stable graft function (stable) on tacrolimus had a 2- to 4.5-fold higher gene expression of CD25, CTLA-4, Foxp3,
and interleukin (IL)-10 than those on CsA (Tac/MMF/ster versus CsA/MMF/ster, n¼ 8 patients/group). Fold difference is expressed as 2DDCt .
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Figure 5 |Regulatory function of T-cell lines derived from patients with stable graft function. Representative proliferation assay
of a co-culture of a T-cell line generated from patient 3 with stable graft function on CsA and patient 2 on tacrolimus (Table 2) irradiated
with 3000 rad, cultured in a 1:1 ratio with T-cell line derived from patient 6 with chronic allograft dysfunction (CAD) on CsA and patient 6 on
tacrolimus (Table 2). From left to right (1) T-cell line from CAD patient specific for HLA-DR1 (42–62)þpeptide HLA-DR1 (42–62); (2) T-cell line
generated from patient with stable graft function specific for HLA-DR1 (42–62)þpeptide HLA-DR1 (42–62); (3) same T-cell line but irradiated;
(4) CAD T-cell line specific for HLA-DR1 (42–62)þ irradiated T-cell line derived from patient with stable function specific for HLA-DR1
(42–62)þpeptide HLA-DR1 (42–62); (5) T-cell line from CAD patient specific for HLA-DR1 (42–62)þ irradiated T-cell line derived from patient
with stable graft function specific for HLA-DR1 (42–62)þpeptide HLA-DR1 (42–62), and neutralizing IL-10 mAb; (6) T-cell line from
patient with stable graft function specific for HLA-DR1 (42–62)þpeptide HLA-DR1 (42–62)þ neutralizing interleukin (IL-10) mAb. Data are
expressed as mean±s.d., repeated three times. Representative example for n¼ 8 T-cell lines/group. CsA, cyclosporine A; HLA, human
lymphocyte antigen; mAb, monoclonal antibody; MMF, mycophenolate mofetil; pep, peptide; ster, steroid; Tac, tacrolimus.
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in patients treated with tacrolimus as compared with CsA.9
Whether this is related in part to the fact of immune
regulation through CD4þCD25þ Tregs is still unknown. A
large body of evidence supports the fact that CD4þCD25þ
Treg cells have potent immune regulatory properties
in vitro6,13,17–20 and are able to downregulate an alloanti-
gen-directed immune response.21,22 Recent studies have
shown that the frequency of circulating CD4þCD25þ
Tregs was associated with a better graft function in patients
after lung and kidney transplantation.23,24 However, little is
known about the effect of the two different calcineurin
inhibitors on CD4þCD25þ Treg generation. CD25 is
expressed on a variety of T cells including effector and
memory T cells that respond aggressively to alloantigens.25
In this study, we demonstrate that isolated T-cell lines from
patients with stable graft function have higher mRNA levels
of CD4, CD25, and Foxp3 as well as higher numbers of T cells
of the CD4þCD25þ regulatory phenotype, as compared
with cell lines from patients with chronic allograft dysfunc-
tion. Thus, the increased levels of Foxp3 together with high
levels of CD25 expression in CD4þ T cells appear to reflect a
Treg phenotype in our patients. This is supported by the
results of our functional analysis. The proliferation of T-cell
lines from patients with CADwas inhibited after co-culture
with T-cell lines from patients with stable graft function in
the presence of donor-specific HLA-DR peptide.
These results are in accordance with our previous study in
an experimental animal model. In that study we demon-
strated that animals injected with Th2-type cell clones
generated from tolerant animals achieved donor-specific
tolerance to the renal allograft, as evidenced by the
acceptance of donor-specific skin allografts. Enrichment of
Tregs producing Th2-type cytokines were also observed in the
target organs by immunohistology. Animals, which received
Th1 cell clones (derived from animals with acutely rejected
allografts), rejected their allografts in an accelerated manner.
This suggests that the generation of Tregs can occur after
transplantation and their effect may be demonstrated, if the
aggressive alloimmune response is controlled, as illustrated in
our previous animal study through the use of a low-dose CsA
protocol. That means that faced with a reduced aggressive
alloreactive T-cell response, Tregs are able to emerge as the
dominant T-cell population and control the immune
response to the allograft.26 T-cell interactions through
production of cytokines such as IL-10 and competition for
antigen-presenting cells are likely to be important compo-
nents of the molecular interactions critical to both linked
suppression and infectious tolerance. The evidence
of enrichment of Tregs, producing Th2 type cytokines, in
allografts from animals injected with Th2 cell clones, suggests
that Tregs operate, at least in part, by locally protecting the
tissues against an allospecific attack. The results also add
to our previous pilot study in transplant patients treated
with CsA.11
How does tacrolimus- and CsA-based immunosuppressive
therapy influence the number and function of Tregs? In other
studies, calcineurin inhibitors were associated with lower
numbers of Tregs in comparison to a sirolimus-based
immunosuppression protocol.6,27,28 We observed higher
numbers of CD4þ 25þ Foxp3þ Tregs in patients treated
with tacrolimus as compared with those taking CsA. These
results are in congruence with the co-culture experiments
that demonstrated a more profound inhibition of the
proliferative response of T-cell lines from patients with
chronic graft dysfunction by T-cell lines from patients with
stable function on tacrolimus, as compared with those on
CsA. Further evidence of a functional role of Tregs is derived
from the inhibitory effects on Treg function of a neutralizing
IL-10 antibody in the co-culture experiments. It can be
speculated that this effect might participate in the improved
graft function of patients treated with tacrolimus
as compared with CsA. Gene expression analysis resulted in
significantly different levels of CD25 and Foxp3 in patients
on a tacrolimus protocol as compared with CsA-based
immunosuppression, only if stable graft function was
present. With regard to the frequency of Tregs, these results
are in accordance with studies in humans that demonstrated
the lowest rate of acute rejections and better graft function in
patients on a Tac/MMF/steroid-based immunosuppressive
protocol.9
Patients with stable graft function had a significantly
higher expression of IL-4 and -10, whereas the cytokines
IL-2, IL-17, TGF-b, and IFN-g were significantly higher in
patients with allograft dysfunction. Interestingly, no increas-
ing in TGF-b in stable patients was observed, indicating
that the immunoregulation in our patients was TGF-b
independent. There were no significant differences with
respect to cytokine expression between patients receiving
tacrolimus or CsA. This could point to a higher activity of
Tregs in patients with stable graft function. The higher levels
of IFN-g in patients with decreased graft function could be
indicative of an ongoing chronic rejection process within the
allograft.
Taken together, T-cell lines from patients on a Tac/MMF/
steroid protocol had a comparably higher percentage of
cells with morphological/molecular characteristics of Tregs
than those on CsA/MMF/steroid. Thus, Tac/MMF/steroid-
based immunosuppression seems to be accompanied
with an increased amount of Tregs in comparison to CsA-
based immunosuppressive protocols in kidney transplant
recipients.
PATIENTS AND METHODS
Patients
From a total of 630 kidney transplant recipients, 107 patients
who were DR mismatched for one of the five candidate HLA-
DR antigens (DR1, DR2, DR3, DR4, and DR7) were included
into the study. All patients were recipients of deceased
donor allografts. Patients were treated with one of the
three following immunosuppressive protocols: cyclosporine
Aþ steroids (CsA/ster; n¼ 30), CsAþMMFþ ster (CsA/MMF/
ster; n¼ 47), or tacrolimusþMMFþ ster (Tac/MMF/ster;
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n¼ 30). Patients who had a serum creatinine consistently
below 1.6mg/dl by month 24 following transplantation were
considered to be stable, whereas patients with a consistently
elevated serum creatinine above 1.6mg/dl at month 24 after
transplantation were assigned to the group with CAD group.
Within the CAD group, T-cell lines were generated only from
patients with biopsy-proven chronic allograft injury (Fig-
ure 1). Matched patients by age, gender, and as much as
possible by HLA were selected from the stable group, and T-
cell lines were generated from these patients (Figure 1). All
patients were followed regularly at 3- to 6-month intervals,
resulting in a completeness index (that is, observed divided
by expected follow-up time) of 0.96. The follow-up time
post-transplant was 60 months. Creatinine levels (mg/dl)
were measured in patients from whom T-cell lines were
generated (day 0¼ day of transplantation, 12 months after
transplantation, 24 months¼ generation of T-cell lines, 48,
and 60 months). Blood samples were collected after obtaining
informed consent. The study protocol was approved by the
local medical ethics committee.
HLA-DRB peptides
A panel of peptides was synthesized corresponding to the
full-length b-chain hypervariable regions of HLA-DRB1*
0101, 1501, 0301, 0401, and 0701 (ProImmune, Littlemore,
UK), as previously reported.11 The peptides used for this
study included the HLA-DRB*0101 (HLA-DR1 residues
6–21, 22–41, 42–62, 63–80, 81–94), HLA-DRB*1501
(HLA-DR2 residues 1–20, 21–40, 41–60, 61–80, 81–94),
HLA-DRB*0301 (HLA-DR3 residues 6–21, 22–41, 42–62,
63–80, 81–94), HLA-DRB*0401 (HLA-DR4 residues 1–18,
21–42, 62–80), and HLA-DRB*0701 (HLA-DR7 residues
1–18, 20–41, 50–65, 62–82).
Establishment of HLA-DRB-specific T-cell lines
PBMCs from patients with stable graft function and from
CAD were collected 24 months after transplantation and
were separated by Ficoll-Hypaque (Amersham Biosciences
AB, Freiburg, Germany) density gradient centrifugation. The
cells were then washed twice in RPMI 1640 medium (Gibco,
Eggenstein-Lopoldshafen, Germany) containing 4% normal
human serum (Gibco), 100U/ml penicillin, 100 mg/ml
streptomycin, 5mmol/l HEPES, 1% nonessential amino
acids, and 1mmol/l sodium pyruvate (Gibco), and spun at
400 g. The cells were counted after resuspension in RPMI
medium that was the same as above, except containing 10%
normal human serum. PBMCs from human renal allograft
recipients (4 106) were cultured separately with 50 mg/ml
of the mismatched donor-derived HLA-DR allopeptides. All
T-cell lines were incubated at 371C with 5% CO2 for 4 days.
The cells (2 105) were repeatedly stimulated with the
donor-specific allopeptides at 7-day intervals in the presence
of irradiated (30Gy) PBMCs from the recipient as antigen-
presenting cells. During the remaining period, the T-cell lines
were cultured in complete medium with 10% human
T-Stim culture supplement without phytohemagglutinin
(BD Biosciences Pharmingen, Heidelberg, Germany). T-cell
lines were generated after three cycles of stimulation.
Luminex analysis
The human cytokine bead assay kit (Luminex, Biosource,
Nivelles, Belgium) was used for measurement of IL-2, IL-2R,
IL-4, IL-10, IL-17, and IFN-g. The assay was performed
according to the manufacturer’s instruction (Biosource).
Briefly, the filter plate was prewetted with 200 ml of working
solution. The beads (25 ml) were pipetted into each well. Sera
or supernatants of the T-cell lines after stimulation with
the peptides (proliferation assay) or standards (50 ml/each)
and supernatants with the neutralizing anti-IL-10 mAb or rat
immunoglobulin-G1 isotope control were pipetted into the
wells and incubated with the beads for 2 h. After washing,
biotin-conjugated detector antibody was added and incu-
bated for 1 h, followed by an incubation of 30min with
R-phycoerythrin-conjugated streptavidin. Analysis was
carried out in the Luminex 100 instrument (Gurce, Nivelles,
Belgium). The results were expressed as pg/ml.
Real-time polymerase chain reaction
mRNA expression of the representative surface molecules and
cytokines (CD4, CD25, CTLA4, Foxp3, IL-10, IFN-g, and
TGF-b) (MWG Biotech, Ebersberg, Germany) was analyzed
in the T-cell lines generated from the recipients by Real Time
PCR assay. The primers used were purchased from Sigma
Genosys (Woodlands, TX). The glyceraldehyde-3-phosphate
dehydrogenase (Sigma Genosys) mRNA levels were analyzed
as housekeeping gene expression for relative quantification
and complementary DNA quality control. Reverse transcrip-
tion from RNA to complementary DNA was carried out by
using iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA).
Initial denaturation at 951C for 15min was followed by 39
cycles of a denaturation step at 951C for 15 s, an annealing
step at 57.51C for 30 s, and an extension step at 721C for 30 s.
The quantification data were analyzed with the LightCycler
analysis software (My Research, Biozym, Oldendorf,
Germany). Reproducibility was confirmed by independent
PCR repeated twice. The average threshold cycle (Ct) value
was calculated as the cycle number at which the fluorescence
of the reporter gene reaches a fixed threshold. The difference
(DCt) between the average Ct values of the samples in the
target wells and those of the housekeeping gene, glyceralde-
hyde-3-phosphate dehydrogenase, was assessed, followed by
the calculation of the difference between the average DCt
values of the PBMCs of the patients or T-cell lines for each
target and the DCt value of healthy volunteers for that target
(DDCt). The relative quantification value, fold difference, is
expressed as 2DDCt .
Proliferation assay
After generation of the T-cell lines, 2 105 cells were cultured
with 10 mg (this dose was used based on our previous
publication showing the dose–response to this peptide)11
of the relevant donor-mismatched HLA-DR allopeptide in
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96-well U-bottom plates (VWR, Darmstadt, Germany).
Human neutralizing antibody, rat anti-human IL-10 mAb
(0.5–25 mg/ml), or rat immunoglobulin-G1 isotope control
antibody (all from PharMingen, San Diego, CA) were added
to the cultures. As the optimal effects of anti-IL-10 mAb were
observed at a concentration of 10 mg/ml, the same dose was
used for anti-IL-10 and isotope control antibodies in the
experiments. Proliferation was measured by 3[H]-thymidine
(1mCi) (Amersham Biosciences Europe, Freiburg, Germany)
incorporation. All assays were set up in quadruplicates, and
the results were expressed as c.p.m.±s.e.m. In the co-culture
system, irradiated (30 Gy) T-cell lines generated from patients
with stable allograft function and on tacrolimus or CsA
immunosuppression (2 105) were incubated with an equal
number of the T-cell lines (ratio 1:1) generated from patients
with CAD and on tacrolimus protocol and the relevant HLA-
DR allopeptide. Background proliferation was assessed by
incubating the cells with culture media alone without the
peptides.
Flow cytometry (fluorescence-activated cell sorter) analysis
T-cell lines (2 105 cells/sample) were stained with
conjugated ECD-anti-human CD3, PC5-anti-human CD4,
ECD-anti-human CD8, and PE-anti-human CD25 (Beckman
Coulter, Krefeld, Germany) mAb at a dilution of 1:100 and
corresponding isotypes. The samples were analyzed by flow
cytometry Beckman Coulter (Krefeld, Germany).
Statistical analysis
Results are expressed as mean±s.d. Characteristics of
patients were compared by Student’s t-test as appropriate.
Variations in peripheral blood count, phenotype, and
functional data were assessed by oneway analysis of variance
with post hoc test by Scheffe for pair wise comparison. Each
experimental condition was repeated three times. A Po0.05
was considered significant.
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